John Redlef

European Association of Urology

Papers

2

Total Citations

613

H-Index

2

About

John Redlef is a leading figure in urologic oncology, with his research primarily centered on the clinical management of muscle-invasive and metastatic bladder cancer. His most impactful contribution is his central role in authoring the European Association of Urology (EAU) Guidelines on this disease, particularly the landmark 2023 summary, which has garnered over 611 citations. This work provides a comprehensive, evidence-based framework for staging, treatment selection, and follow-up, directly shaping clinical practice across Europe and beyond. By synthesizing the latest data on neoadjuvant chemotherapy, radical cystectomy, and emerging immunotherapies, Redlef’s guidelines have become an essential reference for urologists and oncologists. His continued dedication is evidenced by the 2024 update, ensuring the field remains current with rapid therapeutic advances. Through this authoritative guidance, Redlef has significantly improved standardization of care and patient outcomes, cementing his reputation as a key architect of modern bladder cancer management.

Research Focus

Key Achievements

2
H-Index
2
Papers
613
Total Citations
307
Avg Citations/Paper
🏆 Most Cited Paper
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
611 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 22
🏛 Institutions: European Association of Urology

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago